Vaccibody Targeting HPV Infection via DNA Vaccine
By Cormac Sheridan
Wednesday, November 14, 2012
Vaccibody AS received €2 million (US$2.5 million) to have a crack at a problem that has eluded firms with far greater resources: developing an effective therapeutic vaccine against human papillomavirus (HPV) infection.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.